• There were many interesting sections from today’s meeting. Bill Crowley from the MPN Research Foundation was on the ground at the event and shared some highlights:

    • Jason Gotlib presented “What is the Clinical Trial Process”, touching on ethics in the history of clinical trials, how the review boards function, FDA audits of trials, industry monitoring of studies, trial design, and barriers to participation in clinical trials.
    • Srdan Verstovsek gave a rundown of “Current developments in MF treatments”. He spoke of changing guidelines for stem cell transplant and mentioned that MD Anderson will do transplants up to 75, depending on overall health and donor match. He mentioned that sometimes a JAK inhibitor will lower blood counts, and use of a JAK inhibitor has to be individualized. Combinations are encouraged. Two new JAK inhibitors coming up are Pacritinib and Momelotinib. New targets are being investigated with the drugs PRM-151 and Imetelstat.
    • Jerry Spivak gave a talk on “Essential Thrombocythemia, Pathogenesis and Management” that included info on differences between male and female ET patients, with more women affected, but the men with ET tend to have more issues. He also mentioned that migraines are a big problem because of the increase in platelets. If something is not done with the platelet count, that migraine will not improve.

    We’ll report more after the event. If you were at the event or have a question, comment below.